Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 8/20 | 1.00 |
| ▸ | NAAA | Q02083 | 5/20 | 0.58 |
| ▸ | MIF | P14174 | 4/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | BACH1 | O14867 | 1/20 | 0.45 |
| ▸ | MAFK | O60675 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25332310 | 1.00 | TRPA1 (1.00) | TRPA1NAAAMIFGSK3BKEAP1 | |
| SCHEMBL3115548 | 1.00 | TRPA1 (1.00) | TRPA1NAAAMIFGSK3BKEAP1 | |
| SCHEMBL1020887 | 1.00 | TRPA1 (1.00) | TRPA1NAAAMIFGSK3BKEAP1 | |
| SCHEMBL3123984 | 1.00 | TRPA1 (1.00) | TRPA1NAAAMIFGSK3BKEAP1 | |
| SCHEMBL2679812 | 1.00 | TRPA1 (1.00) | TRPA1NAAAMIFGSK3BKEAP1 | |
| Erucin SCHEMBL435774 | 0.98 | — | — | |
| SCHEMBL668271 | 0.91 | — | — | |
| SCHEMBL331092 | 0.81 | TRPA1 (0.68) | TRPA1NAAAMIFGSK3BKEAP1 | |
| Erucin SCHEMBL7579439 | 0.80 | TRPA1 (0.68) | TRPA1NAAAMIFGSK3BKEAP1 | |
| SCHEMBL10585683 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | claimed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | claimed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | claimed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | claimed |
| WO-2016089648-A1 | BACH 1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | VTV THERAPEUTICS LLC (US) | 2016-06-09 | — | — | WO | claimed |
| US-7232583-B2 | Method for preparing isothiocyanate(s) from cruciferous plant material | KINJIRUSHI CO., LTD. (JP) | 2007-06-19 | — | — | US | claimed |
| US-20030064131-A1 | Method for preparing isothiocyanate(s) from cruciferous plant material | JAPANESE R AND D ASSOC. FOR NEW FUNCTIONAL FOODS (JP) | 2003-04-03 | — | — | US | claimed |
| EP-4746880-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | Regencor, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | disclosed |
| CN-119632035-A | Tonsillitis and isothiocyanate compound insecticidal composition, preparation and application thereof | 西北农林科技大学 | 2025-03-18 | — | — | CN | disclosed |
| US-20250066293-A1 | OIL-BASED ISOTHIOCYANATE PRODUCTS AND PROCESSES FOR PREPARING OIL-BASED ISOTHIOCYANATE PRODUCTS | BRASSICA PROTECTION PRODUCTS LLC (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2025024320-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | REGENCOR, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20130028992-A1 | Herbal-Based Solution for Treating Symptoms of Nasal Conditions | WALKER CALEB JAMES (US) | 2013-01-31 | — | — | US | disclosed |
| US-7232583-B2 | Method for preparing isothiocyanate(s) from cruciferous plant material | KINJIRUSHI CO., LTD. (JP) | 2007-06-19 | — | — | US | disclosed |
| CN-1290522-C | Immunity regulating medicine | TAIQING SICHUAN FOOD CO LTD (CN) | 2006-12-20 | — | — | CN | disclosed |
| CN-1593578-A | Immunity regulating medicine | TAIQING SICHUAN FOOD CO LTD (CN) | 2005-03-16 | — | — | CN | disclosed |
| US-20040096528-A1 | Compositions and methods for preserving personal care products | UNICITY INTERNATIONAL, INC. | 2004-05-20 | — | — | US | disclosed |
| US-20030064131-A1 | Method for preparing isothiocyanate(s) from cruciferous plant material | JAPANESE R AND D ASSOC. FOR NEW FUNCTIONAL FOODS (JP) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | TRPA1 2865/4885NAAA 4201/4885MIF 1537/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | TRPA1 4407/4885NAAA 3867/4885MIF 1739/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | TRPA1 2056/4885NAAA 4212/4885MIF 2915/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | TRPA1 3653/4885NAAA 4268/4885MIF 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.